Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 05, 2023 |
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 204,086 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 121,452 · Balance 204,086 F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.
BIOCRYST PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,340,419 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 644 · Balance 1,340,419 F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500. |
| Common StockSEC Table I · non-derivative | IndirectBy wife as co-trustee of the Caroline Stonehouse Irrevocable Trust | 40,000 |
Reported balance
Holding disclosure · report date 2026-08-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 40,000 |
| Common StockSEC Table I · non-derivative | IndirectBy wife as co-trustee of the Samuel Stonehouse Irrevocable Trust | 40,000 |
Reported balance
Holding disclosure · report date 2026-08-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Metsera, Inc.
Report date November 13, 2025 · Filed November 13, 2025
Section 16 reporting ended · disclosed 2025-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 1
1 source rowRow 1 · 2025-11-13 · Disposition to issuer · Disposed 2,688 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,688 |
Reported balance
After 2025-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-13 · Grant · Acquired 2,688 · Balance 2,688 F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.81 · Expires 2035-04-27 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-13 · Disposition to issuer · Disposed 47,730 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F6: This option provided for vesting in 36 substantially equal monthly installments from April 28, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus
F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,
F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.
F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting.
F6: This option provided for vesting in 36 substantially equal monthly installments from April 28, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 2, 2022 23:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 214,917 | $1.42 | $305,182.14 |
DisclosureSEC source: 0001127602-22-026832 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 10:26 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 60,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-024213 · wf-form4_166212879414951.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on September 1, 2023, the one-year anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Jan 4, 2023 20:08 UTC Amendment | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 60,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000354 · wf-form4a_167288087288104.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amendment is being filed to correct the mathematical error in the total amount of securities beneficially owned following the reported transaction on the original Form 4 filed with the SEC on September 2, 2022. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 14:48 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001628280-22-017340 · wf-form4_165540528204428.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 184,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001127602-22-001458 · form4.xml · derivative · entry 5 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 184,000 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 184,000 | $15.04 | $2,767,360.00 |
DisclosureSEC source: 0001127602-22-001458 · form4.xml · nonDerivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,602 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 184,000 | $4.73 | $870,320.00 |
DisclosureSEC source: 0001127602-22-001458 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:40 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 21,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000413 · wf-form4_164148001306460.xml · derivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021. F2 · derivative.expiration_date: The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:40 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 21,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000413 · wf-form4_164148001306460.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. Read SEC document |
| January 04, 2022 Filed Sep 1, 2022 16:39 UTC Amendment | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 21,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-024156 · wf-form4a_166206473196248.xml · derivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,054 Underlying: Common Stock · 21,054 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F3 · derivative.exercise_date: The RSUs were granted on January 4, 2021 and vested in full upon the one year anniversary. F3 · derivative.expiration_date: The RSUs were granted on January 4, 2021 and vested in full upon the one year anniversary. F1 · derivative.underlying_shares: This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022. F1 · balance_after: This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022. Read SEC document |
| January 04, 2022 Filed Sep 1, 2022 16:39 UTC Amendment | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 21,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-024156 · wf-form4a_166206473196248.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022. F1 · balance_after: This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 574,500 | $0.00 Strike: $11.43 | $0.00 |
DisclosureSEC source: 0001127602-21-031116 · form4.xml · derivative · entry 6 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,500 Underlying: Common Stock · 574,500 shares Expires 2031-12-14 F4 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031116 · form4.xml · nonDerivative · entry 5 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,602 F3 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| September 01, 2021 Filed Dec 16, 2021 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031116 · form4.xml · nonDerivative · entry 4 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust Disclosed balance after: 5,000 F2 · kind: Reflects a gift of shares by the reporting person to the Caroline Stonehouse Irrevocable Trust. Read SEC document |
| September 01, 2021 Filed Dec 16, 2021 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031116 · form4.xml · nonDerivative · entry 3 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust Disclosed balance after: 5,000 F1 · kind: Reflects a gift of shares by the reporting person to the Samuel Stonehouse Irrevocable Trust. Read SEC document |
| September 01, 2021 Filed Dec 16, 2021 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031116 · form4.xml · nonDerivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,602 F2 · kind: Reflects a gift of shares by the reporting person to the Caroline Stonehouse Irrevocable Trust. Read SEC document |
| September 01, 2021 Filed Dec 16, 2021 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031116 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,602 F1 · kind: Reflects a gift of shares by the reporting person to the Samuel Stonehouse Irrevocable Trust. Read SEC document |
| June 15, 2021 Filed Jul 7, 2021 20:30 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-045947 · doc4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-06-14 Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:40 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 21,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000101 · wf-form4_160989004218833.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,054 Underlying: Common Stock · 21,054 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs will vest in full upon the one year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs will vest in full upon the one year anniversary of the date of grant. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 870,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-20-031780 · form4.xml · derivative · entry 4 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,000 Underlying: Common Stock · 870,000 shares Expires 2030-12-15 F3 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 134,278 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001127602-20-031780 · form4.xml · derivative · entry 3 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 134,278 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 134,278 | $8.32 | $1,117,192.96 |
DisclosureSEC source: 0001127602-20-031780 · form4.xml · nonDerivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,086 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.18 to $8.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 134,278 | $4.15 | $557,253.70 |
DisclosureSEC source: 0001127602-20-031780 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 157,250 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-20-030693 · form4.xml · derivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,250 Underlying: Common Stock · 157,250 shares Expires 2029-12-17 F2 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001127602-20-030693 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2023-08-08 F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 16:46 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001628280-20-009546 · wf-form4_159234037743780.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 157,250 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-20-016759 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,250 Underlying: Common Stock · 157,250 shares Expires 2029-12-17 F1 · date: On May 13, 2020, the Board of Directors determined that the initial data from part 3 of the BCX9930 phase 1 clinical trial represented successful results from a proof of concept study of BCX9930 and, as a result, that one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 27,140 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001127602-20-007615 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,140 Underlying: Common Stock · 27,140 shares Expires 2025-01-01 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to Mr. Stonehouse in January 2015 has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 47,495 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001127602-20-006477 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,495 Underlying: Common Stock · 47,495 shares Expires 2025-01-01 F1 · date: On February 18, 2019, the company announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to Mr. Stonehouse in January 2015 has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 314,500 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035542 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,500 Underlying: Common Stock · 314,500 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:17 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 50,000 | $1.45 | $72,500.00 |
DisclosureSEC source: 0001127602-19-033035 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,086 Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 16:03 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001358403-19-000091 · wf-form4_156054261591323.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 3,568 | $8.07 | $28,793.76 |
DisclosureSEC source: 0001127602-19-000701 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,106 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 675,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001127602-18-037163 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2028-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001127602-18-035394 · form4.xml · derivative · entry 3 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2019-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2018. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 80,000 | $9.12 | $729,600.00 |
DisclosureSEC source: 0001127602-18-035394 · form4.xml · nonDerivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,674 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.93 to $9.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 80,000 | $1.20 | $96,000.00 |
DisclosureSEC source: 0001127602-18-035394 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2018. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 16:01 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | PurchaseCommon Stock | 10,000 | $4.56 | $45,600.00 |
DisclosureSEC source: 0001358403-18-000102 · wf-form4_154214286960560.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 16:31 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001358403-18-000061 · wf-form4_152935385344279.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2019 Annual Meeting of stockholders. Read SEC document |
| May 17, 2018 Filed May 21, 2018 13:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 70,427 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-18-018216 · form4.xml · derivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,573 Underlying: Common Stock · 70,427 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 21, 2018 13:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 70,427 | $1.42 | $100,006.34 |
DisclosureSEC source: 0001127602-18-018216 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 56,949 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-009568 · form4.xml · derivative · entry 3 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,949 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 43,224 | $4.97 | $214,823.28 |
DisclosureSEC source: 0001127602-18-009568 · form4.xml · nonDerivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,092 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 56,949 | $3.26 | $185,653.74 |
DisclosureSEC source: 0001127602-18-009568 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 9,584 | $5.59 | $53,574.56 |
DisclosureSEC source: 0001127602-18-002228 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,367 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 13:59 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 2,716 | $4.91 | $13,335.56 |
DisclosureSEC source: 0001127602-18-000295 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,951 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035395 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:26 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 40,710 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001127602-17-026934 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,710 Underlying: Common Stock · 40,710 shares Expires 2025-01-01 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded to the reporting person in January 2015 has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 16:44 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001358403-17-000101 · wf-form4_149755946592701.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2018 Annual Meeting of stockholders. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009089 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.